XML 91 R70.htm IDEA: XBRL DOCUMENT v3.3.1.900
Intangible Assets and Goodwill (Details) - USD ($)
1 Months Ended 12 Months Ended
Oct. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Jun. 04, 2015
Mar. 31, 2013
Indefinite-Lived Intangible Assets [Line Items]            
Intangible assets   $ 284,340,000 $ 29,000,000      
Intangible asset impairment charges   0 0 $ 412,900,000    
Goodwill   50,384,000 39,915,000      
VX-222Asset            
Indefinite-Lived Intangible Assets [Line Items]            
Fair value of intangible asset           $ 0
Intangible asset impairment charges       412,900,000    
Increase in net loss related to impairment charge       $ 285,300,000    
Net increase to the Company's net loss per share related to the impairment charge (usd per share)       $ 1.27    
Research and Development Arrangement | VX-222Asset            
Indefinite-Lived Intangible Assets [Line Items]            
Intangible assets       $ 412,900,000    
Change in deferred income taxes       $ 127,600,000    
BioAxone Biosciences, Inc            
Indefinite-Lived Intangible Assets [Line Items]            
In-process research and development intangible assets     29,000,000      
Parion Sciences, Inc            
Indefinite-Lived Intangible Assets [Line Items]            
Intangible assets         $ 255,340,000  
Goodwill         10,468,000  
Goodwill acquired during period   10,500,000        
Goodwill expected to be tax deductible   0        
Variable Interest Entity, Primary Beneficiary            
Indefinite-Lived Intangible Assets [Line Items]            
Intangible assets   284,340,000 29,000,000      
Goodwill   19,391,000 8,923,000      
Variable Interest Entity, Primary Beneficiary | BioAxone Biosciences, Inc            
Indefinite-Lived Intangible Assets [Line Items]            
In-process research and development intangible assets     $ 29,000,000      
Variable Interest Entity, Primary Beneficiary | Parion Sciences, Inc            
Indefinite-Lived Intangible Assets [Line Items]            
In-process research and development intangible assets   $ 284,300,000        
Intangible assets         $ 255,300,000  
Indefinite-lived Intangible Assets | Variable Interest Entity, Primary Beneficiary | BioAxone Biosciences, Inc            
Indefinite-Lived Intangible Assets [Line Items]            
Discount rate used to estimate fair value (percent) 7.50%          
Indefinite-lived Intangible Assets | Variable Interest Entity, Primary Beneficiary | Parion Sciences, Inc            
Indefinite-Lived Intangible Assets [Line Items]            
Discount rate used to estimate fair value (percent) 7.10%